PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378597
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378597
The Global Orthopedic Regenerative Medicine Market is estimated to be valued at US$ 9.53 billion in 2023, and is expected to exhibit a CAGR of 10.7% during the forecast period (2023-2030).
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 9.53 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 10.70% | 2030 Value Projection: | US$ 19.39 Bn |
Orthopedic regenerative medicine are therapies developed from biologic (natural) substances that can be used by orthopaedic specialists to: Help relieve pain and other symptoms of certain orthopaedic conditions, such as early osteoarthritis, which may help delay the need for surgery. With regenerative orthopedic therapy, healing elements that the body naturally produces are extracted, prepared, and then injected into the areas of the body that need healing, all without drugs or surgery. Orthobiologics can be used to treat degenerative conditions such as certain forms of arthritis, as well as sports injuries and traumas. Regenerative medicine may help some patients avoid orthopedic surgery completely. Regenerative orthopedics may improve pain and discomfort of the musculoskeletal system and enhance the healing of orthopedic conditions, such as injuries of a tendon, ligament, bone, muscle, spinal disc, meniscus of the knee, cartilage or other musculoskeletal tissue. Most of these parts of the body have a relatively poor ability to heal on their own. The idea behind regenerative medicine is to help these tissues heal better.
Increasing product launches by the key players in the market are expected to drive the growth of the global orthopedic regenerative medicine market over the forecast period. For instance, in June 2020, Aziyo Biologics, Inc., a commercial-stage regenerative medicine company creating the next generation of differentiated products to improve outcomes in patients undergoing surgery, announced the launch of its newest OsteGro family product, OsteGro V, a viable cell bone matrix containing cancellous bone particles as well as demineralized cortical bone particles and fibers to enhance product handling. The product is optimized to protect and preserve native bone cells through Aziyo Biologics, Inc.'s proprietary process.
Global Orthopedic Regenerative Medicine Market Detailed Segmentation: